DB:PH7

Stock Analysis Report

Executive Summary

Phylogica Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Phylogica's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.5%

PH7

1.0%

DE Biotechs

1.4%

DE Market


1 Year Return

300.0%

PH7

1.3%

DE Biotechs

3.7%

DE Market

Return vs Industry: PH7 exceeded the German Biotechs industry which returned 1.3% over the past year.

Return vs Market: PH7 exceeded the German Market which returned 3.7% over the past year.


Shareholder returns

PH7IndustryMarket
7 Day12.5%1.0%1.4%
30 Dayn/a-5.5%1.3%
90 Dayn/a-4.4%3.4%
1 Year300.0%300.0%1.5%1.3%7.0%3.7%
3 Yearn/a67.3%65.6%18.5%8.3%
5 Year763.9%620.0%12.9%10.4%42.2%22.9%

Price Volatility Vs. Market

How volatile is Phylogica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Phylogica undervalued compared to its fair value and its price relative to the market?

25.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate PH7's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PH7's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PH7 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PH7 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PH7's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PH7 is overvalued based on its PB Ratio (25.6x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Phylogica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

42.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Phylogica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Phylogica's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Phylogica competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Phylogica performed over the past 5 years?

-12.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PH7 is unprofitable, and losses have increased over the past 5 years at a rate of -12.7% per year.

Accelerating Growth: Unable to compare PH7's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PH7 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: PH7 has a negative Return on Equity (-64.76%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PH7 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PH7 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Phylogica's financial position?


Financial Position Analysis

Short Term Liabilities: PH7's short term assets (A$6.2M) exceeds its short term liabilities (A$401.9K)

Long Term Liabilities: PH7 has no long term liabilities


Debt to Equity History and Analysis

Debt Level: PH7 is debt free.

Reducing Debt: PH7 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: PH7 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PH7's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PH7 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PH7 has sufficient cash runway for 1.013550 years if free cash flow continues to reduce at historical rates of -7% each year.


Next Steps

Dividend

What is Phylogica's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PH7's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PH7's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PH7's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PH7's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PH7's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Phylogica's salary, the management and board of directors tenure and is there insider trading?

AU$482k

CEO Compensation


CEO

Rohan Hockings (36yo)

1.5yrs

Tenure

AU$482,336

Compensation

Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, is Chief Executive Officer at Phylogica Ltd since April 11, 2018 and has been its a Director since November 30, 2018. He manages a special purpose acquisiti ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Rohan's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Rohan's compensation has increased whilst the company is unprofitable.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$4,76024 Apr 19
Australian Land Pty. Ltd.
EntityCompany
Shares300,000
Max PriceAU$0.016
BuyAU$2,408,52904 Dec 18
Australian Land Pty. Ltd.
EntityCompany
Shares124,500,000
Max PriceAU$0.019
BuyAU$644,85404 Dec 18
Bernard Hockings
EntityIndividual
Shares33,333,334
Max PriceAU$0.019

Ownership Breakdown


Management Team

  • Rohan Hockings (36yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: AU$482.34k
  • Kevin Hart (57yo)

    Company Secretary & CFO

    • Tenure: 2.3yrs
    • Compensation: AU$165.90k

Board Members

  • Erica Golemis

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Trevor Payne

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Robert

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marie Bogoyevitch

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Johnathan Licht

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Rob Aalberse

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Patrick Holt

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Gregory Weiss

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Rohan Hockings (36yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: AU$482.34k
  • Alan Tribe (71yo)

    Non-Executive Chair of the Board

    • Tenure: 1.5yrs
    • Compensation: AU$66.95k

Company Information

Phylogica Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Phylogica Limited
  • Ticker: PH7
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$161.229m
  • Listing Market Cap: AU$99.086m
  • Shares outstanding: 2.44b
  • Website: https://phylogica.com

Number of Employees


Location

  • Phylogica Limited
  • Harry Perkins Institute
  • 6 Verdun Street
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PYCASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMar 2005
PH7DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2005
PH7BST (Boerse-Stuttgart)YesOrdinary SharesDEEURMar 2005
PYCCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMar 2005

Biography

Phylogica Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. Its Phylomer libraries contain various  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 21:21
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.